Abstract
Acute myeloid leukemia (AML) patients who can tolerate intensive chemotherapy regimen, are considered as “fit” patients. Given the lack of clarity on definition of “fit patients, this study aims to describe the proportion of 1st line therapy given to AML patients in Japan, identify the demographic characteristics of patients receiving each treatment regimen, treatment patterns, and healthcare resource and cost utilization from a retrospective hospital administrative data.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
